Zhitong Finance App News, Junshi Biotech (01877.HK) announced that recently, the company received the “Drug Supplement Application Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) to approve the transition from conditional approval to routine approval for treprilizumab injection (trade name: Tuoyi®, product code: JS001) single drug for platinum-containing chemotherapy failure, including progression of locally advanced or metastatic urothelial carcinoma within 12 months of neoadjuvant or adjuvant chemotherapy.

Zhitong Finance App News, Junshi Biotech (01877.HK) announced that recently, the company received the “Drug Supplement Application Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) to approve the transition from conditional approval to routine approval for treprilizumab injection (trade name: Tuoyi®, product code: JS001) single drug for platinum-containing chemotherapy failure, including progression of locally advanced or metastatic urothelial carcinoma within 12 months of neoadjuvant or adjuvant chemotherapy.